As the U.S. Supreme Court’s 2024-25 term draws to a close, with rulings expected to wrap up by the end of June, FGS’s SCOTUS Litigation team is keeping an eye on the biggest cases yet to be decided. In the coming weeks, the Court will be the final voice on a range of critical issues including the boundaries of the First Amendment, the permissibility of nation-wide injunctions and whether states can ban healthcare for trans kids. These, and others, are poised to have major implications for America’s legal landscape – and FGS’s clients:
Trump v. CASA will rule on the Administration’s executive order ending birthright citizenship; in addition to resolving that important question, the case will likely address whether federal judges can continue to use nationwide injunctions to halt executive actions.
United States v. Skrmetti will resolve whether states are allowed to deny gender-affirming care to trans youth.
Food and Drug Administration v. R.J. Reynolds Vapor Co. will determine whether a manufacturer may file for review in an appellate circuit where it does not reside, if the petition is joined by a seller of the manufacturer's products in that circuit. This could allow manufacturers to “forum shop,” and could prove relevant for FGS clients facing potential product liability litigation.
FGS’s SCOTUS Litigation team is tracking these cases and standing by to provide counsel to companies and clients interested in the outcomes.